Comparing the effectiveness of Chinese patent medicines containing red yeast rice on hyperlipidaemia: A network meta‐analysis of randomized controlled trials

Xu, Guanghui; Lin, Mingxin; Dai, Xiaoli; Hu, Jingqing

doi:10.1002/edm2.314

Cited by 10 publications

(8 citation statements)

References 37 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The effect of RYR was similar to that of low-intensity/low-dose statins on LDL-C (MD 0.03 mmol/L; 95% CI −0.36, 0.41 [ p = 0.89]) and TC (MD −0.05 mmol/L; 95% CI −0.28, 0.18 [ p = 0.67]) [ 10 ]. Finally, a network meta-analysis of 47 randomized controlled trials involving 4824 subjects, evaluating three different Chinese RYR supplements (most commonly Xuezhikang 600 mg twice daily), showed that RYR significantly reduced LDL-C, TC, and triglycerides versus placebo [ 67 ]. No significant differences in the levels of these parameters were observed with RYR versus simvastatin, although a ranking analysis suggested that Xuezhikang (surface under the cumulative ranking [SUCRA] value 82.6%) was more likely than simvastatin (SUCRA value 74.9%) to be effective in reducing LDL-C [ 67 ].…”

Section: Effect Of Ryr On Ldl-c Plasma Level and Estimated Risk Of Ascvdmentioning

confidence: 99%

Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review

et al. 2023

View full text Add to dashboard Cite

Reducing low-density lipoprotein cholesterol (LDL-C) levels is a key target for lowering cardiovascular risk and preventing atherosclerotic cardiovascular disease (ASCVD). Red yeast rice (RYR) is a nutraceutical widely used as a lipid-lowering dietary supplement. The main cholesterol-lowering components of RYR are monacolins, particularly monacolin K, which is structurally identical to lovastatin and targets the same key enzyme of cholesterol biosynthesis. RYR supplementation reduces LDL-C levels by approximately 15–34% versus placebo, with a similar effect to low-dose, first-generation statins in subjects with mild-to-moderate dyslipidemia. RYR has also demonstrated beneficial reductions of up to 45% versus placebo in the risk of ASCVD events in secondary prevention studies. RYR at a dose that provides about 3 mg/d of monacolin K is well tolerated, with an adverse event profile similar to that of low-dose statins. RYR is therefore a treatment option for lowering LDL-C levels and ASCVD risk for people with mild-to-moderate hypercholesterolemia who are ineligible for statin therapy, particularly those who are unable to implement lifestyle modifications, and also for people who are eligible for statin therapy but who are unwilling to take a pharmacologic therapy.

show abstract

Section: Effect Of Ryr On Ldl-c Plasma Level and Estimated Risk Of Ascvdmentioning

confidence: 99%

Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review

et al. 2023

View full text Add to dashboard Cite

show abstract

“…Many available studies have evaluated the efficacy of RYR preparations on lipid profiles, and (to a lesser extent) CVD outcomes. The results of such studies have been summarised in several meta-analyses [18,21,22]. Beneficial effects of RYR supplementation on plasma lipid profile have been recognised for several years.…”

Section: Efficacy Of Red-yeast Rice In Dyslipidaemias and Cardiovascu...mentioning

confidence: 99%

“…However, the authors did suggest that owing to limitations inherent in their study, the validity of their results should be confirmed in large, well-designed, multicentre, prospective RCTs. [22].…”

Section: Efficacy Of Red-yeast Rice In Dyslipidaemias and Cardiovascu...mentioning

confidence: 99%

Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel

Banach

Catapano

Cicero

et al. 2022

Pharmacological Research

View full text Add to dashboard Cite

“…ZBT has the functions of regulating lipid, stabilizing carotid plaque, improving vascular endothelial function and so on, and has few side effects (Su and Hu, 2021). Several clinical studies have shown that ZBT has a good lipid-lowering effect (Xu et al, 2010;Zhao et al, 2017;Xu et al, 2018;Xu et al, 2022). In a mouse model, ZBT can affect the MAPK-ERK-TLRs pathway by down-regulating the expressions of TLR4 and P-ERK1/2 proteins, it can inhibit the transduction of inflammatory signaling pathway, prevent the occurrence and development of inflammation, regulate blood lipids, and antagonize insulin resistance to protect the liver (Liao et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

Efficacy and safety of zhibitai in the treatment of hyperlipidemia: A systematic review and meta-analysis

Wang

Pang

et al. 2022

Front. Pharmacol.

View full text Add to dashboard Cite

Objective: To evaluate the efficacy and safety of Zhibitai (ZBT) in the treatment of patients with hyperlipidemia (HLP).Methods: A search of 8 electronic databases was conducted to find randomized controlled trials (RCTs), to evaluate the efficacy and safety of ZBT for the treatment of HLP. The risk of bias in randomized controlled trials was assessed by using the Cochrane Collaboration Risk of Bias tool for randomized controlled trials 2.0 (RoB 2.0). The primary outcomes were the levels of triglyceride (TG), total cholesterol (TC), low-density lipoprotein cholesterol (LDL-C), and high-density lipoprotein cholesterol (HDL-C). The total effective rate served as the secondary outcome. The incidence of adverse events was considered the safety outcome. Review Manager 5.4 was used to conduct meta-analyses. Data were pooled by random-effects or fixed-effects model to obtain the mean difference (MD), risk ratio (RR), odds ratio (OR), and 95% confidence interval (CI).Results: There were 28 eligible RCTs with a total of 2,952 participants. Overall, we verified that ZBT plus conventional therapy (CT) was superior to CT for the treatment of HLP [TC: MD = −0.50, 95% CI (−0.80, −0.19); TG: MD = −0.38, 95% CI (−0.49, −0.27); LDL-C: MD = −0.50, 95% CI (−0.69, −0.31); HDL-C: MD = 0.17, 95% CI (0.11, 0.24); total effective rate: OR = 4.26, 95% CI (2.28, 7.95)]. There were no significant differences in the primary outcomes between ZBT alone vs. CT (p > 0.05). For safety, the ZBT group (with CT or alone) outperformed the CT group [ZBT alone: RR = 0.51, 95% CI (0.32, 0.81); ZBT plus CT: RR = 0.51, 95% CI (0.30, 0.89)]. For each outcome, the subgroups and the sensitivity analysis matched the overall results.Conclusion: ZBT may be safe and beneficial to HLP patients, especially for serum lipid management. ZBT can be used along with CT for the treatment of HLP. However, it is necessary to conduct more rigorous RCTs to confirm these findings.Systematic Review Registration: [https://www.crd.york.ac.uk/PROSPERO/], identifier [CRD42022316251].

show abstract

Comparing the effectiveness of Chinese patent medicines containing red yeast rice on hyperlipidaemia: A network meta‐analysis of randomized controlled trials

Abstract: This is an open access article under the terms of the Creative Commons Attribution License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

Cited by 10 publications

References 37 publications

Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review

Red Yeast Rice for the Improvement of Lipid Profiles in Mild-to-Moderate Hypercholesterolemia: A Narrative Review

Red yeast rice for dyslipidaemias and cardiovascular risk reduction: A position paper of the International Lipid Expert Panel

Efficacy and safety of zhibitai in the treatment of hyperlipidemia: A systematic review and meta-analysis

Contact Info

Product

Resources

About